BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study-Reference-Cited by-同舟云学术

BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study

Published:2018-08-20 Issue:12 Volume:25 Page:3701-3708
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Marchetti Claudia,De Leo Rossella,Musella Angela,D’Indinosante Marco,Capoluongo Ettore,Minucci Angelo,Benedetti Panici Pierluigi,Scambia Giovanni,Fagotti Anna

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/article/10.1245/s10434-018-6700-6/fulltext.html

Reference33 articles.

1. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced- stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013; 10: 211–224.

2. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–393.

3. Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011; 22:1127–1132.

4. Petrillo M, Marchetti C, De Leo R, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017; 217(3): 334.e1–334.e9.

5. Bookman MA, Tyczynski JE, Espirito JL,Wilson TW, Fernandes AW. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol. 2017;146(1): 58–63.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer;Critical Reviews in Oncology/Hematology;2024-10

2. Molecular biology as a driver in therapeutic choices for ovarian cancer;International Journal of Gynecologic Cancer;2024-08-28

3. Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status;Gynecologic Oncology;2024-08

4. Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?;Pleura and Peritoneum;2024-07-08

5. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04